Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ponatinib + blinatumomab
- Development stage
- Phase 3
- Lead developer
- Takeda
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Ponatinib + blinatumomab is a combination regimen of two distinct pharmaceuticals used primarily for the treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Ponatinib is an oral small molecule tyrosine kinase inhibitor that targets BCR-ABL1 and other kinases, while blinatumomab is a bispecific T-cell engager antibody construct that directs cytotoxic T cells to CD19-expressing B cells. This chemotherapy-free combination has demonstrated high rates of complete molecular response and minimal residual disease negativity in both newly diagnosed and relapsed/refractory Ph+ ALL patients. The regimen may reduce the need for allogeneic stem cell transplantation and mitigate toxicities associated with traditional chemotherapy[1][3][4][5][6].
- Other names
- blinatumomab plus ponatinibblinatumomab and ponatinib
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on ponatinib + blinatumomab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ponatinib + blinatumomab.